News
Evrysdi Use Extended to Infants Younger Than 2 Months With Spinal Muscular Atrophy
The approval was based on efficacy and safety data from the phase 2 RAINBOWFISH study, which included presymptomatic infants aged from birth to 6 weeks old with genetically diagnosed SMA.